

**MINUTE  
AREA DRUG AND THERAPEUTICS COMMITTEE  
WEDNESDAY 16<sup>th</sup> March @10am  
Microsoft Teams Meeting**

**In Attendance:**

Dr Mehrdad Malekian	Mrs Karen Patterson	Mrs Christine Gilmour
Mr George Lindsay	Mrs Kirsty MacFarlane	Dr David Semple
Dr Iain Hathorn	Mrs Carol McGoff	Mr Bill Angus
Mrs Gail Richardson	Dr Tyra Smyth (from Item 2022/46 10)	

<b>2022/37</b>	<b>1.</b>	<b><u>Apologies for Absence</u></b>  Ms Katrina Maroni, Mr John Milne, Mrs Linda Johnstone, Dr Stephanie Dundas, Mrs Emma Harris, Ms Ann Auld, Mrs Penny Brankin	
<b>2022/38</b>	<b>2.</b>	<b><u>Declaration of Interest</u></b>  There were no declarations of interest.	
<b>2022/39</b>	<b>3.</b>	<b><u>Matters arising not covered elsewhere on the agenda</u></b>	
	<b>a.</b>	<b><u>Ratification of minutes of meeting 16<sup>th</sup> February 2022</u></b>  The minute was accepted as an accurate record and can now be published.	<b>IM</b>
	<b>b.</b>	<b><u>Oxygen Prescribing in Acute Settings</u></b>  There was a useful discussion which concluded that this issue is best taken forward at the Acute Clinical Governance Committee and can now be omitted from future ADTC agendas.	
	<b>c.</b>	<b><u>Steroid Emergency Cards</u></b>  This will be rolled over till the April meeting.	<b>CG</b>
	<b>d.</b>	<b><u>SGLT2 Patient Information</u></b>  Mr Lindsay and Mrs Patterson reported on a useful meeting held yesterday with a range of stakeholders. An action plan is in place for review by Acute Governance structures and communications including an updated Patient Information Leaflet to go to multidisciplinary clinicians in both Primary Care and Acute Care. This item can be omitted from future ADTC agendas.	
	<b>e.</b>	<b><u>Management of Cholesterol in Adults</u></b>  This item is anticipated for the April agenda.	

**SMC ADVICE****FULL SUBMISSIONS****Atidarsagene autotemcel (Libmeldy®) SMC2413**

This was noted.

**Venetoclax (Venclyxto®) SMC2412**

This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN).

**Upadacitinib (Rinvoq®) SMC2417**

This was noted and will be referred to dermatology specialists.

**NON SUBMISSIONS****Belimumab (Benlysta®) SMC2483**

This was noted.

**Carfilzomib (Kyprolis®) SMC2484**

This was noted.

**Ibrutinib (Imbruvica®) SMC2485**

This was noted.

**Update on the interim assessment approach in response to COVID19**

This is a pragmatic approach to minimise delay in patient access as a result of the COVID-19 pandemic. Following review by the SMC executive, SMC advice for two abbreviated submissions noted below will be published on the SMC website on **Monday 11 April 2022**.

**ABBREVIATED SUBMISSIONS****Risankizumab (Skyrizi®) SMC2459**

This was noted and will be referred to rheumatology specialists.

**Fedratinib (Inrebic®) SMC2462**

This was noted and will be referred to haematology specialists.

**AMENDED ADVICE****Sotorasib (Lumykras®) SMC2443**

This was noted.

**Berotrastat (Orladeyo®) SMC2405**

This was noted.

**FOR INFORMATION**

**Note: Budget Impact templates will be sent to NHS Board contacts and Directors of Pharmacy under separate cover.**

Upadacitinib (Rinvoq®) SMC2417 – Please note budget impact templates will follow at a later date for this submission.

This was noted.

	<p><b><u>Paediatric Licence Extensions</u></b></p> <p>These were noted.</p>	
2022/41	<p><b>5. <u>SMC follow up</u></b></p> <p>Mrs McGoff talked the committee through the SMC follow up which had been previously circulated.</p> <p>Feedback for SMC2405 Berotralstat (Orladeyo®) was provided with a query over how prescriptions would be prescribed, dispensed and collected for this item.</p> <p>Feedback for SMC2408 Cenobamate (Ontozry®) was provided. The Committee was in agreement with this. The corresponding ADTC bulletin will be updated accordingly.</p>	
2022/42	<p><b>6. <u>Lanarkshire Formulary</u></b></p> <p>Mrs McGoff raised two formulary amendments. The first was updated information regarding missed doses of methadone following a paper which was ratified by the Addictions Quality Governance Group.</p> <p>The second was the amendment of the buprenorphine entry to meet the Medication Assisted Treatment (MAT) standards.</p>	<b>CMcG</b>
2022/43	<p><b>7. <u>Clinical Protocols</u></b></p> <p><b>a. <u>Management of patients with T2DM and cardiovascular disease</u></b></p> <p>There was useful discussion around the guidance for canagliflozin and heart failure and the difference between heart failure with preserved ejection fraction versus heart failure with reduced ejection fraction. The advice relating to SGLT2 inhibitors and “sick day rules” was also noted.</p> <p>The guideline was approved with a review date of one year in anticipation that this is a quickly changing area of practice.</p> <p>Dr Malekian will feedback to the authors.</p> <p><b>b. <u>Tralokinumab</u></b></p> <p>This was agreed. Dr Malekian will feedback to the authors.</p> <p><b>c. <u>A guideline for Periprocedure management of coagulation.</u></b></p> <p>Mrs Richardson and Mrs Patterson had some points of detail regarding consistent use of units and reference ranges within the document. Dr Maklekian had some comments relating to bleeding risk assessment methodology and risk stratification. Mrs Richardson will share her thoughts with Dr Malekian who will then discuss the guideline further with Dr Hung.</p>	<p><b>MM</b></p> <p><b>MM</b></p> <p><b>GR</b> <b>MM</b></p>

	<p><b>d. <u>Clozapine induced Hypomobility Guidance</u></b></p> <p>Dr Semple talked through the rational for the guideline which was agreed. Mr Lindsay will feedback to Ms Templeton so that it can be placed on the guideline website and APP. It was also agreed that a suitable link be included in the Formulary.</p> <p><b>e. <u>NHS Lanarkshire Guideline on Management of Low B12 in Adults</u></b></p> <p>This was agreed. Mr Lindsay will feedback to Dr Hung.</p>	<p><b>GL CMcG</b></p> <p><b>GL</b></p>
<p><b>2022/44 8.</b></p>	<p><b><u>ADTC New Medicines Decisions</u></b></p> <p>This was noted.</p>	
<p><b>2022/45 9.</b></p>	<p><b><u>Unlicensed Medicines</u></b></p> <p>There was nil to note at today's meeting.</p>	
<p><b>2022/46 10.</b></p>	<p><b><u>Patient Group Directions</u></b></p> <p>The PGD for podopyllotoxin was agreed. Mr Lindsay will feedback to sexual health.</p> <p>There was also a useful discussion regarding PGD procedures which agreed that:</p> <ul style="list-style-type: none"> <li>• Clinical review and authorisation will take place at the ADTC or AAGI as appropriate</li> <li>• The proposed statements to clarify responsibility for Lead Managers/Professionals, Senior Nurse/Professionals and Healthcare Professionals applying the PGDs were useful and can be incorporated into new PGDs from 1<sup>st</sup> April.</li> </ul> <p>Systems to assure timely review of PGDS and other documents are challenging and it was agreed that a specific meeting including Dr Malekian, Amanda Minns, Christine Gilmour, George Lindsay, Margot Russell and Kirsty Macfarlane be convened to consider best solutions.</p> <p>The NHS Grampian policy for PGDs was noted. The systems and structures within NHS Grampian do not directly align with NHS Lanarkshire but consideration can be given to adopting/adapting some of their processes.</p>	<p><b>GL</b></p> <p><b>GL</b></p>
<p><b>2022/47 11.</b></p>	<p><b><u>Medication and Clinical risk in Lanarkshire</u></b>  <a href="https://www.gov.uk/drug-safety-update">https://www.gov.uk/drug-safety-update</a></p> <p>This was noted.</p>	

2022/48 12.	<p><b><u>Regional Cancer Advisory Network</u></b></p> <p>There was nil to note at today's meeting.</p>	
2022/49 13.	<p><b><u>Patient Safety Alerts</u></b></p> <p>There was nil to note at today's meeting.</p>	
2022/50 14.	<p><b><u>Lay member related items</u></b></p> <p>There was nil to note at today's meeting.</p>	
2022/51 15.	<p><b><u>ADTCC Correspondence</u></b></p> <p><b>a. ADTCC Forum – Sapropterin update</b></p> <p>It was noted that feedback about the short time scale for responses had already been given. The ADTC will further review the guidance statement when it is published.</p> <p><b>b. Scottish Medicines Consortium - Request for expressions of interest for Membership</b></p> <p>Members are giving this consideration.</p>	
2022/52 16.	<p><b><u>Pharmacy &amp; NMAHP Prescribing Governance</u></b></p> <p>This item was covered in the discussion about PGDs above.</p>	
2022/53 17.	<p><b><u>AOCB</u></b></p> <p>There was no AOCB at today's meeting.</p>	
2022/54 18.	<p><b><u>Date of next meeting</u></b></p> <p>Wednesday 20<sup>th</sup> April 2022 10am @ Microsoft Teams</p>	